曾从美股退市， 即将进行第三次IPO。 文｜温世君 编辑｜孙春芳 来源｜棱镜（ID：lengjing_qqfinance） 封面来源｜IC photo "一篇虚假报告，就可以让迈瑞股价大受影响，每年仅维护费就要耗费1500万美元。"迈瑞医疗创始人、新加坡首富李西廷，曾经回忆公司在美股上市时的 被动处境。 迈瑞医疗是中国最大的医疗器械企业——产品覆盖全国近11万家医疗机构及99%以上的三甲医院，2024年营收达367.26亿元。 此前，这家公司已先后进行过美股、A股两场IPO。74岁的李西廷，早已是资本市场的老玩家。 2025年10月15日，迈瑞医疗公告称：已审议通过赴港上市方案，将发行H股并在香港联交所主板挂牌。 迈瑞医疗，这家李西廷在1991年40岁时辞去铁饭碗，"下海"创办的企业，正准备迎来第三场IPO。 两次IPO成就新加坡首富 2016年，作别美股后，那个时代画上句号。李西廷开始寻求"回A"。 医疗健康是A股投资者偏爱的赛道。虽转战深交所主板未果，但2018年10月，迈瑞医疗最终成功登陆深交所创业板。此次IPO迈瑞医疗用约10%的股份， 募资59.3亿元人民币，在当时直接创下创业板开板以来的最大募资纪 ...

Core Viewpoint - The announcement of a significant interim dividend of 6.551 billion yuan by Industrial Fulian highlights the ongoing trend of substantial interim dividends in the A-share market, reflecting strong corporate performance and confidence in future growth [1][2]. Group 1: Interim Dividend Trends - As of October 21, 843 A-share companies have announced 850 interim dividend plans, totaling 662.026 billion yuan, nearing the total for the previous year [1][2]. - Leading companies such as Industrial Fulian, China CRRC, Hengli Petrochemical, and Mindray Medical are at the forefront of this interim dividend wave, showcasing their commitment to shareholder returns [1][2]. Group 2: Company Performance - Industrial Fulian reported a revenue of 360.76 billion yuan in the first half of 2025, a year-on-year increase of 35.6%, with a net profit of 12.11 billion yuan, up 38.6%, both achieving historical highs [3]. - Contemporary Amperex Technology Co., Ltd. (CATL) also announced a substantial dividend, with a net profit of 30.5 billion yuan in the first half of 2025, reflecting a year-on-year growth of 33.3% [3]. Group 3: Market Implications - The surge in interim dividends is seen as a reflection of robust corporate earnings and cash flow, reinforcing the notion that core domestic assets can provide stable cash returns, thus enhancing investor confidence [2][4]. - The recent revisions to the corporate governance guidelines by the China Securities Regulatory Commission encourage companies to increase the frequency of cash dividends, promoting a shift towards regular dividend distributions [4]. - The positive correlation between dividend announcements and stock price performance is evident, with Industrial Fulian's stock price doubling this year and CATL's stock rising by 41.72%, indicating strong market recognition of quality dividend-paying stocks [4].

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Core Viewpoint - Mindray Medical is preparing for its third IPO, this time in Hong Kong, after previously going public in the US and A-share markets. The company has faced challenges, including a significant drop in stock price due to a false report and a decline in revenue and profit in recent periods [4][5][22]. Company Overview - Mindray Medical is the largest medical device company in China, with products covering nearly 110,000 medical institutions and over 99% of top-tier hospitals. The projected revenue for 2024 is 36.726 billion yuan [5]. - The company has undergone two previous IPOs: the first on the New York Stock Exchange in 2006 and the second on the Shenzhen Stock Exchange in 2018, where it raised 5.93 billion yuan, setting a record for the ChiNext board [11][12]. IPO History - Mindray Medical went public on the NYSE in 2006, but was privatized in 2016 for $3.3 billion after its market value fell to around 17 billion yuan. The company successfully returned to the A-share market in 2018 [10][11]. - Following its return to A-shares, Mindray's market value soared to 200 billion yuan within a year, and it reached a peak market value of 600 billion yuan during the pandemic [12][22]. Recent Developments - On October 15, 2025, Mindray announced its plan to list H-shares on the Hong Kong Stock Exchange, with a similar issuance ratio to its A-share IPO [7][16]. - The company has seen a decline in revenue by 18.45% and a net profit drop of 32.94% in the latest half-year report, indicating challenges in the current market environment [22]. Leadership Changes - Co-founder Cheng Minghe has stepped down as vice chairman, although he retains a board seat. His shareholding has decreased from 5.29% to 3.83% through multiple sell-offs [16][19]. - The current leadership includes Li Xiting, who remains actively involved in the company, and other long-term executives who are positioned to take over in the future [21][22]. Market Position and Strategy - Mindray Medical's stock price has increased by 6.8% from April to October 2025, which is significantly lower than the nearly 25% rise in the Shanghai Composite Index during the same period [23]. - The company is focusing on mergers and acquisitions as a strategy for business expansion, having made significant purchases in recent years, including a 75% stake in DiaSys for €1.15 billion [24]. Financial Health - As of mid-2025, Mindray Medical's market capitalization is approximately 270.9 billion yuan, with goodwill amounting to nearly 11.5 billion yuan, indicating a substantial investment in acquisitions [24]. - The company maintains a cash reserve of around 16.9 billion yuan, suggesting manageable financial risk despite the challenges faced [24].

Core Viewpoint - The A-share market has witnessed a significant surge in mid-term dividend announcements, with 843 companies planning to distribute a total of 662.03 billion yuan, nearly matching the total for the previous year [1][6]. Group 1: Dividend Distribution Overview - A total of 843 A-share companies have announced 850 mid-term dividend plans, amounting to 6620.26 billion yuan, which is close to last year's total mid-term dividends [1][6]. - Major companies like China Mobile and Industrial and Commercial Bank are leading with mid-term dividends exceeding 50 billion yuan each, while industry leaders such as Industrial Fulian and China CRRC have also joined the dividend distribution [3][6]. - Among the 843 companies, 442 have a market capitalization exceeding 10 billion yuan, highlighting the involvement of large-cap firms in enhancing shareholder returns [5]. Group 2: Financial Highlights - The total planned mid-term dividends of 6620.26 billion yuan is a remarkable figure, with 79 companies planning dividends over 1 billion yuan, and 14 companies exceeding 10 billion yuan, indicating a trend towards regular dividend distributions [6][10]. - The increase in dividend frequency is notable, with 7 companies planning to distribute dividends twice within the year, reflecting a shift towards more consistent shareholder returns [7]. Group 3: Factors Driving Dividend Surge - The new "National Nine Articles" policy has played a crucial role in promoting cash dividends among listed companies, mandating stricter regulations on companies with low or no dividends [9]. - Companies are showing strong profitability and cash flow, with industry leaders like Midea Group and CATL planning dividends exceeding 10 billion yuan, demonstrating their financial strength [10]. Group 4: Market Impact - The substantial mid-term dividends are expected to attract more long-term funds into the market, particularly from pension and insurance funds seeking stable returns [13]. - Consistent dividend payments can stabilize market expectations and reduce volatility, providing a "safe haven" for investors during market downturns [13]. Group 5: Investor Considerations - Investors are advised to remain cautious of potential "false dividend traps," where companies may announce high dividends despite poor financial health [15]. - Rational investment strategies are emphasized, encouraging investors to consider their risk tolerance and the overall financial health of companies when making investment decisions [16]. Conclusion - The current mid-term dividend wave in the A-share market signifies a positive shift towards enhanced shareholder returns and a more mature market environment, with expectations for continued growth in dividend distributions [17].

Core Viewpoint - The article discusses the performance of the ChiNext 50 ETF (159682) as of October 22, highlighting a decline in its value and the performance of its major holdings [1] Group 1: ETF Performance - The ChiNext 50 ETF (159682) closed down 0.99% at 1.404 yuan, with a trading volume of 178 million yuan [1] - Since its inception on December 23, 2022, the fund has achieved a return of 41.87%, with a monthly return of 0.45% [1] Group 2: Major Holdings Performance - Major holdings in the ChiNext 50 ETF include: - CATL down 1.10% - East Money down 1.30% - Huichuan Technology up 0.98% - Zhongji Xuchuang up 0.70% - Mindray down 1.15% - Xinyisheng down 0.14% - Sungrow down 3.25% - Shenghong Technology down 1.40% - Yiwei Lithium Energy down 2.67% - Tonghuashun down 1.19% [1]

Group 1 - The "Quality Month" series of activities in Shenzhen concluded successfully, focusing on comprehensive quality management with a systematic framework of "1+4+N" [1] - Over 20,000 enterprises and industry organizations participated, with approximately 1.2 million citizens involved [1] - The framework includes a launch ceremony, four core sectors (government leadership, industry recognition, industrial empowerment, and public participation), and over 140 unique activities organized by various districts and departments [1] Group 2 - Shenzhen showcased its achievements in quality enhancement, with companies like Mindray Medical and China General Nuclear Power Engineering Design receiving nominations for the China Quality Award [1] - Shenzhen has pioneered the "Shenzhen Quality Investment" model, which was presented at the China Quality (Nanjing) Conference, attracting significant attention [1] - The Shenzhen Market Supervision Administration released the "Quality Strong Chain Implementation Guide" to promote overall quality improvement across the industrial chain [1] Group 3 - The "Shenzhen Enterprise Brand Going Global Service Day" event aimed to enhance the international influence of local brands and expand their global market presence [2] - Various activities, including the Chief Quality Officer Forum and quality innovation competitions, effectively stimulated quality innovation among enterprises and employees [2] - The QC group competitions addressed over 120 frontline issues, generating economic benefits exceeding 100 million [2]

Core Insights - As of October 21, a total of 66 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Fanwei Network, which has seen net buying for 10 trading days [1] - Other notable stocks with significant consecutive net inflows include Mindray Medical, Yingke Medical, Shenjian Co., Xingqi Eye Medicine, Maixinlin, Deep Technology, Diweier, and Haide Co. [1]

Group 1: Fixed Income Market Insights - Institutional trading behavior shows stabilization, with a focus on improving allocation strength. The median duration of long-term pure bond funds decreased by 0.23 years compared to October 10, with specific median durations for pure interest rate bonds, interest rate bonds, and credit bonds at -0.40 years, -0.35 years, and -0.21 years respectively [1] - In the primary market, there was a decline in subscription demand for government bonds and policy financial bonds, particularly for ultra-long bonds. In the secondary market, major banks are expected to face lower supply pressure for ultra-long bonds in Q4 compared to Q2 and Q3 [1] - Asset management products show a recovery in net value for interest rate and credit bond funds, with most funds recording negative returns over the past three months [1] Group 2: Economic Data Analysis - The macroeconomic landscape in September 2025 is characterized by strong production but weak demand, with GDP growth of 4.8% year-on-year, indicating a slowdown compared to Q2. The cumulative growth for the first three quarters is 5.2%, suggesting that achieving the annual growth target of around 5% is feasible [2][20] - The economic disparity is evident, with production significantly outperforming expectations, particularly in high-tech manufacturing, while consumption and investment indicators are generally weak. Retail sales growth has slowed for four consecutive months [20] - The government has initiated macro policies to address the weak demand, including a new policy financial tool totaling 500 billion yuan aimed at supplementing project capital [20] Group 3: Pharmaceutical Industry Insights - The IVD sector experienced a decline in revenue and net profit in Q2 2025, with a year-on-year revenue drop of 10.0% and a net profit decrease of 17.1%. The overall revenue for the first half of 2025 also reflects a downward trend [29] - The impact of medical reform has led to a decrease in IVD product prices, creating opportunities for domestic substitutes. The competitive environment and regulatory changes have delayed hospital procurement, further affecting pricing [29] - The international market for IVD is expanding, with significant growth potential as the international market capacity is 4-5 times that of China, and companies are accelerating their overseas strategies [31] Group 4: Coal Industry Developments - Domestic thermal coal prices have surged unexpectedly, with prices reaching 748 yuan/ton as of October 17, 2025, marking a week-on-week increase of 43 yuan/ton. The price increases in production areas are even more pronounced [6] - Despite being in the off-peak season for electricity consumption, demand remains strong due to early heating in northern regions, which is expected to support coal prices [6] - The annual target price for thermal coal has been raised to 750-800 yuan/ton, driven by supply constraints and seasonal demand expectations [6] Group 5: Chemical Industry Overview - The chemical industry is approaching the end of its current cycle, with demand expected to stabilize. The construction and export sectors are showing resilience, while the real estate cycle continues to decline [9][33] - Global trends indicate a shift from cost-efficiency to regional cooperation models due to geopolitical tensions, impacting investment and trade patterns [33] - The domestic chemical sector is experiencing a significant decline in capital expenditure, with supply pressures expected to ease as the industry approaches a bottoming phase [33]

Core Viewpoint - Mindray Medical is initiating its third IPO in Hong Kong to expand its financing channels and support its global and AI business growth despite facing challenges in the domestic market and cash flow concerns [2][3][5]. Group 1: Financial Performance and IPO Details - Mindray Medical's stock price is 223.57 CNY per share, with a total market capitalization of approximately 271.1 billion CNY [6]. - The company plans to issue H shares not exceeding 10% of the total share capital post-issue, with a potential fundraising scale of at least 1 billion USD [9]. - Despite having substantial cash reserves of 16.967 billion CNY and a low debt ratio of about 25%, the company's operating cash flow has significantly decreased, with a net cash flow of only 3.922 billion CNY in the first half of 2025, a drop of 53.83% year-on-year [10][11]. Group 2: Market Challenges and Strategic Goals - Domestic revenue has declined by 30% to 8.41 billion CNY, attributed to delayed procurement cycles and price reductions in public hospital equipment purchases [11]. - The company aims to increase its international revenue share to over 70% by 2030, with a current international business revenue growth of 5.39% [14]. - Mindray's goodwill has increased to 11.51 billion CNY, accounting for 19.6% of total assets, raising concerns about potential impairment risks if future acquisitions do not meet profit expectations [15]. Group 3: R&D and Innovation - Mindray Medical is increasing its R&D investment, with 4.008 billion CNY allocated in 2024, representing 10.91% of revenue [16]. - The company has developed AI medical systems, including the "Qiyuan" clinical model, which assists in clinical decision-making and has been implemented in top hospitals [16]. Group 4: Management Changes and Controversies - Recent management changes include the resignation of co-founder Cheng Minghe, which has sparked market discussions regarding corporate governance [18]. - Mindray faced scrutiny over a low-price bidding incident, where a project budget of 3 million CNY was won with a bid of only 1,000 CNY, leading to an investigation [19][20].